Researchers developed new animal models that faithfully reproduce the evolution and malignancy of different human tumors. This allows for parallel tumor progression, prediction of relapses, and assessment of effective treatments in a controlled laboratory setting.
Researchers identified two subtypes of breast cancer, Epi-Basal and Epi-Luminal B, which differ in their epigenetic patterns. The subtype Epi-Luminal B is associated with reduced survival rates and requires adjuvant chemotherapy.
Researchers developed a genetic test that can predict acute rejection up to three months in advance. The non-invasive test measures gene expression levels and can identify patients at high risk of rejection, allowing for tailored immunosuppressive therapy.
Researchers have discovered that tumor cells secrete exosomes containing proteins capable of transforming neighboring cells into tumor cells, promoting tumor growth. Dicer protein is identified as a key factor in this process and may serve as a biomarker or therapeutic target.
Researchers found that the brain separates emotional responses from explicit memories of fear, leading to uncontrolled emotional reactions in post-traumatic stress disorder. This study may help develop new therapeutic strategies for these disorders.
Researchers identified CD44 as a potential marker to select patients unresponsive to Sorafenib, a common liver cancer treatment. Patients with a less differentiated mesenchymal phenotype expressing CD44 tend to resist Sorafenib's action, highlighting the need for alternative therapies.
Researchers have characterized the dog's epigenome and transferred the results to human breast cancer, revealing significant alterations in gene modulation and common epigenetic mechanisms. The findings suggest that targeting these epigenetic alterations may help slow disease progression.
Researchers have identified 5 genes differentially expressed in normal accompanying cells of colorectal tumors. These genes can be used to classify tumors and predict patient outcomes, enabling clinicians to make informed decisions about chemotherapy treatment.
A study published in Nature found that regulatory DNA regions preceding genes play a crucial role in tumor development, with altered function leading to gene mutations and cancer progression.
Researchers at IDIBELL and University of Barcelona discover HERC2 regulates p53 activity, a key step in tumor progression. The study suggests mutations in HERC2 may be associated with cancer in humans.
Researchers at IDIBELL and ICO have tested a new therapeutic combination of conventional chemotherapy and rapamycin to combat resistant sarcomas. The Phase I trial showed promising results, with the tumor stopping growth and not recovering after treatment, and has launched a Phase II clinical trial.
Researchers at IDIBELL have discovered that combining effective drugs for Parkinson's disease reduces some Rett syndrome symptoms in mice. This finding offers a potential starting point for studying the effectiveness of similar treatments in humans.
Researchers have identified a new mechanism for controlling genetic material altered in cancer, involving ultra-conserved RNA molecules that regulate microRNA activity. This discovery could lead to a better understanding of cancer development and potentially inform new treatments.
Two new genes, FOXM1 and CENPF, linked to more aggressive prostate cancer have been discovered. A new approach in the treatment of these patients is being developed using computer algorithms and biomarkers.
Researchers have found epigenetic changes that increase the risk of developing cancer, which affect gene expression without altering the genes themselves. The study analyzed 3,500 tumors and identified genetic polymorphisms associated with an increased risk of cancer, highlighting DNA methylation as a key factor in the disease
Research discovers that tumor cells' reliance on glucose for energy is driven by a defective gene that fails to degrade glucose receptors, making them 'addicted' to sugar. The study offers new insights into the Warburg effect and potential treatment strategies.
Researchers found a significant decrease in snuff smoke exposure among non-smokers in Spain after the implementation of tobacco control laws. The perception of being exposed to snuff smoke decreased by 36.5% at home and 25% overall, indicating smokers are restricting indoor smoking.
Researchers have identified a subgroup of schizophrenia patients with motor disorders, characterized by low levels of A2A adenosine receptors in the basal ganglia. The study proposes a specific combination therapy involving antipsychotics and A2A agonists to reduce symptoms.
Scientists have identified an epigenetic lesion in the hippocampus of Alzheimer's patients, which regulates tau protein and may contribute to disease progression. This discovery provides a potential new target for future therapies, offering hope for improved treatment options.
An international study has developed a refined method to identify people at risk for certain inherited cancers associated with Lynch syndrome. The study uses genetic data from thousands of variants identified worldwide to classify variants of unknown significance and improve genetic counseling for families.
The study identifies MAX as a tumor suppressor gene in aggressive lung cancer, which regulates the expression of BRG1 through direct recruitment to the MAX promoter. The depletion of BRG1 hinders cell growth and is synthetic lethal with MAX-deficient tumors.
Researchers found that loss of RPL5 or RPL11 prevents cell cycle arrest but impairs proliferation due to reduced ribosome content and translation capacity. This discovery highlights a new mechanism for controlling cell growth, relying on the essential role of these ribosomal proteins in biogenesis.
Researchers at IDIBELL describe the key role of separase protein in regulating mitosis and ensuring correct genetic inheritance. The study identifies two new substrates that contribute to the Hippo tumor suppressor pathway, advancing knowledge of this process.
Researchers discovered epigenetic differences in colon cancer cells that render them resistant to chemotherapy drugs. The findings suggest that the inactivation of a specific gene may be responsible for this phenomenon.
Researchers at IDIBELL have identified a key component of the complement system that plays a major role in rejecting xenotransplanted porcine chondrocytes. Inhibiting this component, C5, protects cartilage tissue from rejection and inflammation.
A study by IDIBELL researchers has identified a mechanism inducing tumor cell migration in liver cancer, suggesting that patients with overactivated TGFb and high CXCR4 levels may benefit from TGFb inhibitory therapy. The findings provide new insights into the molecular mechanisms underlying liver cancer progression.
A study by researchers from IDIBELL and University of Barcelona found that language learning depends on the structure and function of the arcuate fasciculus, a bundle of nerve fibers connecting auditory regions with motor areas. Individuals with more myelinated connections in this area performed better at word learning.
A study of 191 patients found that ADHD-related impulsivity worsens the prognosis for adults with eating disorders, particularly those with bulimia and binge-eating disorders. The research also identified age and low self-direction as risk factors for developing an eating disorder.
Researchers discovered significant brain epigenome changes from birth to adolescence, transforming the frontal cortex and shaping communication spaces between neurons. The study's findings have profound implications for understanding brain biology and potentially treating neurodevelopmental disorders like autism and schizophrenia.
The study reveals that noncoding 5S rRNA regulates the Hdm2-p53 checkpoint, allowing p53 to rise and induce cell death. This discovery suggests an ancient evolutionary link between ribosome biogenesis and cancer.
Researchers at IDIBELL and ICO aim to study pathogenicity of variants in DNA repair genes MSH2 and MSH6. The funding will improve molecular diagnostics of Lynch syndrome, enabling better risk assessment and prevention measures.
A study by IDIBELL researchers recommends the use of faster and more potent antithrombotic drugs in high-risk heart attack patients. The study found that only 25% of patients responded to aspirin and 10% responded to clopidogrel, leading to a recommendation for stronger alternative treatments.
IDIBELL has licensed a patent for a repositioned drug to treat X-linked adrenoleukodystrophy, a rare neurodegenerative disease. The patented product has shown promise in laboratory studies, but further research is needed before its application can be considered.
A study found altered noncoding long chain RNA sequences in Rett Syndrome, which regulates gene expression and neurotransmitter function. The research could lead to new therapeutic strategies targeting lncRNA molecules or GABA receptors.
Researchers have identified a new subtype of ataxia, SCA37, which has been found in multiple families across Spain. This discovery opens the door for personalized therapies and diagnostic tools, allowing patients to receive treatment before symptoms appear.
Researchers identified three BRCA1 gene variants as pathogenic, increasing breast and ovarian cancer risk. These findings will improve genetic counseling and allow for personalized cancer assessment.
Researchers found that patient age influences the onset of pathological gambling disorder and its clinical course. Younger patients are more likely to be impulsive, while older patients seek to modulate negative emotional states.
Researchers at IDIBELL and VHIR have developed a treatment using adult mesenchymal stem cells to regenerate damaged lung tissue and reduce inflammation. The licensed product has shown promising results in animal models of acute respiratory distress and allergic asthma.
Researchers have identified a genetic cause of developmental delay in Amish individuals, characterized by learning disabilities and hyperactivity. The HERC2 gene mutation leads to an unstable protein that causes similar symptoms to Angelman syndrome.
A recent review of 400 patients with Wolfram syndrome reveals that 15% do not meet current diagnostic criteria, highlighting the need for revision. The study proposes expanding the diagnostic criteria to identify two of four clinical features, which would diagnose up to 98% of patients.
Researchers at IDIBELL-Bellvitge Biomedical Research Institute have developed a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The new protocol has been shown to be highly sensitive and specific, reducing costs and time for obtaining results.
A new selective target in muscle regeneration has been identified by researchers at the Bellvitge Biomedical Research Institute. The association of alpha-enolase protein and plasmin plays a crucial role in regulating immune cell attraction and formation of new muscle tissue from stem cells.
Researchers developed a diagnostic tool identifying breast cancer cells' ability to spread, based on their lipid profile. The technique, Raman microspectroscopy, has shown promise for routine cytological diagnosis and may be extended to other tumors.
Researchers identified an epigenetic change associated with a higher risk of breast cancer in the sick twin before clinical diagnosis. The DOK7 gene showed pathological methylation gain, indicating potential as a novel biomarker for early detection.
Researchers found that rapamycin can extract a balance between UCHL1 and its mirror protein, holding them together in the cytoplasm to correct mistakes in Parkinson's disease. The drug may delay onset of diseases like Alzheimer's and Parkinson's by correcting protein imbalance.
Researchers at IDIBELL and ICO have developed new animal models for cancer research, including orthotopic implants of human tumor tissues in mice. These models mimic the growth of human tumors and response to chemotherapy, paving the way for personalized medicine against various cancers.
Researchers identified epigenetic changes that occur in adult stem cells to generate different body tissues. The study shows that laboratory-created muscle and bone cells resemble those found in nature and are biologically secure for implantation.
Recent research in epigenetics has identified two key tests that can predict brain tumor sensitivity to temozolomide and distinguish prostate cancer from benign growth. New epigenetic biomarkers are being rapidly developed to predict treatment performance and weaknesses of tumors.
Research by IDIBELL-UB reveals that exposure to IDPN nitrile leads to accumulations of neurofilaments similar to those found in amyotrophic lateral sclerosis. This finding suggests a potential link between environmental toxins and ALS, with implications for new treatment approaches.
An international study reveals that the epigenome of newborns and centenarians differs, with older individuals showing a distorted epigenome that has lost key switches. Reversibility of this process is possible through dietary changes or drug use.